

1 **Identification of a new, Rab14-dependent, endo-lysosomal pathway**

2 Evgeniya Trofimenko¹, Yuta Homma², Mitsunori Fukuda² and Christian Widmann^{1,3}

3

4 ¹Department of Biomedical Sciences, University of Lausanne, Lausanne, Switzerland

5 ²Laboratory of Membrane Trafficking Mechanisms, Department of Integrative Life
6 Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Miyagi, Japan

7

8

9 ³Corresponding author

10

11

12

13

14 Keywords: endocytosis, endosomes, Rab5, Rab7, Rab14, cell-penetrating peptides,

15 homeodomains, homeoproteins, polyamines

16

17

18

19 Address correspondence: Christian Widmann, Department of Biomedical Sciences,

20 Rue du Bugnon 7, 1005 Lausanne, Switzerland, Phone: +41 21 692 5123, Fax: +41

21 21 692 5505, E-mail: Christian.Widmann@unil.ch.

22

23 **Summary**

24 Cells can endocytose material from the surrounding environment. Endocytosis and
25 endosome dynamics are controlled by proteins of the small GTPase Rab family.
26 Several endocytosis pathways have been described (e.g. clathrin-mediated
27 endocytosis, macropinocytosis, CLIC/GEEC pathway). Besides possible recycling
28 routes to the plasma membrane and various organelles, these pathways all appear to
29 funnel the endocytosed material to Rab5-positive early endosomes that then mature
30 into Rab7-positive late endosomes/lysosomes. By studying the uptake of a series of
31 cell-penetrating peptides (CPPs) used in research and clinic, we have discovered a
32 second endocytic pathway that moves material to late endosomes/lysosomes and that
33 is fully independent of Rab5 and Rab7 but requires the Rab14 protein. This newly
34 identified pathway differs from the conventional Rab5-dependent endocytosis at the
35 stage of vesicle formation already and is not affected by a series of compounds that
36 inhibit the Rab5-dependent pathway. The Rab14-dependent pathway is also used by
37 physiological cationic molecules such as polyamines and homeodomains found in
38 homeoproteins. Rab14 is expressed by the last eukaryotic common ancestor. The
39 Rab14-dependent pathway may therefore correspond to a primordial endosomal
40 pathway taken by cationic cargos.

41

42 **Introduction**

43 Endocytosis is a major entry route used by cells to take up a variety of extracellular
44 substances ranging from nutrients, fluid phase material, growth factors, hormones,
45 receptors, cellular penetrating peptides (CPPs), viruses or bacteria. Various forms of
46 endocytosis have been described, the main routes being clathrin-mediated
47 endocytosis, macropinocytosis, and the clathrin-independent
48 carrier/glycosylphosphatidylinositol-anchored protein enriched endocytic compartment
49 (CLIC/GEEC) pathway [reviewed in ¹⁻⁵]. Which form of endocytosis is used and the
50 ultimate fate of the endocytosed material depend on the nature of the substances being
51 taken up by cells.

52 Endocytic vesicles (endosomes) are formed by membrane invaginations, actin-driven
53 membrane protrusions (in the case of macropinocytosis for example), or ruffling. In the
54 case of clathrin-mediated endocytosis, vesicle formation is triggered through the
55 detection of the endosomal cargo by AP2 adaptor domains and subsequent
56 recruitment of clathrin triskelions ^{6,7}. Several AP2 adaptors bound to the plasma
57 membrane through PI(4,5)P₂ are necessary for efficient clathrin binding ⁷.
58 Accumulation of AP2/clathrin complexes (within seconds) at the membrane leads to
59 membrane bending and endocytic vesicle formation ⁶⁻⁸.

60 Endosomes are dynamic structures that undergo fusion and fission events ⁹. Early
61 endosomes mature into multivesicular bodies (MVBs), late endosomes and finally
62 lysosomes, where degradation of the endocytosed material occurs ^{10,11}. The
63 endocytosed material can also be recycled back to the plasma membrane or trafficked
64 towards other cellular compartments ¹⁰⁻¹².

65 Each stage of endosomal maturation is meticulously controlled by the sequential
66 recruitment of various endosomal protein and lipids. For example, on the early
67 endosomes, Rab5, activated by its guanine exchange factor (GEF) Rabex-5, controls
68 local generation of PI(3)P by recruiting the Vps34 PI3 kinase. This in turn leads to
69 recruitment of EEA1 via its capacity to bind PI(3)P through its FYVE domain. EEA1
70 can also directly interact with the active GTP-bound form of Rab5. The ability of EEA1
71 to bind simultaneously Rab5 and PI(3)P on separate vesicles makes it a tethering
72 protein that contributes to endosomal fusion ¹³. Vps34 knock-out in mammalian cells
73 leads to enlarged early endosomes and interruption of the progression of endocytosed
74 cargo to lysosomes ¹⁴. Vesicle maturation proceeds through the recruitment of the
75 Mon1-Ccz1 complex that interacts with Rab5 and PI(3)P. The Mon1-Ccz1 complex has
76 a GEF activity towards Rab7 that leads to the activation of this small GTPase on
77 endosomes [reviewed in ^{11,15}]. Concomitantly, Rab5 GTPase-activating protein (GAP)
78 turns off Rab5 and promotes release of the latter from early endosomes. Hence, Rab5
79 and Rab7 regulate essential steps in the endocytic pathway that moves endocytosed
80 material to lysosome. The Rab5/Rab7-controlled endocytic pathway is currently the
81 only molecularly characterized route taken by endocytosed material that end up in
82 lysosomes ^{2,5,15}.

83 In this study we show that endocytosed CPPs, homeoproteins, and polyamines, follow
84 a newly discovered endosomal pathway towards lysosomes that requires Rab14 but
85 not Rab5 or Rab7. Endocytosis of CPPs is also unaffected by phosphoinositide 3-
86 kinase (PI3K) inhibitors or various pharmacological agents known to inhibit the uptake
87 of classical cargos such as transferrin and dextran. This work therefore defines a
88 second independent endocytic maturation pathway that moves endocytosed material
89 to lysosomes.

91 Results

92 **CPPs employ unconventional endocytosis**

93 CPPs can be used for intracellular transport of bioactive cargo into cells ¹⁶⁻²⁸. Various
94 non-exclusive mechanisms of CPP endocytosis have been proposed ^{16-23,27,29-31}.
95 However, there is no consensus and clarity regarding the precise nature of the
96 endosomal pathway used by CPPs and its underlying mechanisms. CPPs additionally
97 enter cells through direct translocation via water pores that are formed as a
98 consequence of membrane megapolarization induced by the CPP themselves and the
99 activity of potassium channels ³². Direct translocation can be inhibited through plasma
100 membrane depolarization or invalidation of specific potassium channels (e.g. KCNN4
101 in HeLa cells), without affecting endocytosis of CPPs ³², transferrin ³³ or vesicular
102 stomatitis virus (VSV) ³³. Here, we took advantage of KCNN4 knockout HeLa cells to
103 study specifically endocytosis in the absence of possible confounding effects mediated
104 by CPP direct translocation. To investigate the endocytic pathway employed by CPPs,
105 we phenotypically characterized CPP containing vesicles (Figure S1A-B) for the
106 presence of early (Rab5 and EEA1) and late (Rab7 and Lamp1) endosomal markers.
107 We selected five most commonly used CPPs in research and in clinic (TAT, R9,
108 Penetratin, MAP and Transportan) as well as TAT-RasGAP₃₁₇₋₃₂₆, a prototypical TAT-
109 cargo complex ^{32,34-44}. Pulse-chase experiments (Figure 1A-B and S1B) demonstrated
110 colocalization of transferrin, EGF and dextran with EEA1, Rab5A and Rab5B at early
111 time points, and Rab7 and Lamp1 at later time points. These results are consistent
112 with previous knowledge that these molecules enter cells through clathrin-mediated
113 endocytosis (transferrin and EGF) and macropinocytosis (dextran). To ensure that
114 ectopic expression of endosomal markers does not interfere with normal endocytosis,
115 we compared the pattern of EEA1-positive and Lamp1-positive vesicle, which we found

116 to be qualitatively similar in control cells and in cells expressing ectopic GFP-tagged
117 versions of these markers (Figure S1C). Moreover, ectopic expression of the tagged
118 EEA1 and Lamp1 constructs did not alter the kinetics of transferrin colocalization with
119 EEA1- or Lamp1-positive vesicles (Figure S1D). These results indicate that ectopic
120 expression of fluorescent endosomal markers, in live cells in particular, does not
121 appear to affect endocytic processes. CPPs were found in EEA1- and Lamp1-positive
122 vesicles at early and late time points, respectively (Figure 1A-B and S1A) but
123 surprisingly only a minority of CPP-containing vesicles were positive for Rab5 and
124 Rab7 (Figure 1A-B). Even though the selected CPPs have different physico-chemical
125 properties they all carry positive charges within their sequence and appear to be found
126 in the same endocytic vesicles (Figure S1E).

127 To rule out that association of Rab5 with CPP-containing vesicles could be transient,
128 we performed experiments at 20°C such that endosomal maturation is considerably
129 slowed down, as can be observed for transferrin (Figure 1C, left). However, CPP-
130 positive endosomes remained mostly Rab5-negative (Figure 1C). Additionally, Rab5-
131 and Rab7-positive CPP-containing vesicles were only marginally detected in the
132 continuous presence of the CPPs despite extensive colocalization with EEA1 (Figure
133 S1F). High resolution confocal images showed that TAT was found inside EEA1-
134 positive vesicles already a few minutes after being added to cells (Figure 1D)
135 confirming that CPPs are indeed located in EEA1-positive endosomes. In addition,
136 TAT-RasGAP₃₁₇₋₃₂₆ did not interfere with the progression of transferrin through early
137 and late endosomes (Figure S1G) and did not lead to generation of aberrant
138 endosomes bearing EEA1 and Lamp1 at the same time (Figure S1H). This indicates
139 that CPPs do not reprogram the manner by which cells take up material through
140 classical endocytosis. Lack of colocalization with Rab5A and Rab7 was observed

141 previously for tryptophane/arginine-rich peptide WRAP linked to siRNA ⁴⁵. Additionally,
142 based on visual inspection of representative images in literature, R8 and TAT also
143 colocalize only partially with Rab5A ⁴⁶.

144 We then used pharmacological agents such as EIPA ⁴⁷, IPA3 ^{48,49}, ML7 ^{50,51},
145 Jasplakinolide ⁵² and Cytochalasin D ^{53,54} that block distinct steps of endocytic vesicle
146 formation and maturation, such as actin filament polymerization, Na⁺/H⁺ exchange
147 inhibition, as well as macropinosome formation and closure, to determine whether
148 these steps are parts of the CPP endocytic pathway. We observed no effect of these
149 inhibitors on the internalization of TAT-RasGAP₃₁₇₋₃₂₆ in contrast to what was seen for
150 dextran uptake (Figure S2A-B). Additionally, as opposed to transferrin internalization,
151 the early stages of CPP endocytosis were dynamin-independent (Figure S2C).

152 Lipids such as phosphoinositides (PIs) that can be phosphorylated at positions 3, 4, or
153 5 of the inositol ring, represent another type of markers of endocytosis. For example,
154 PI(4,5)P₂ is enriched in the plasma membrane, whereas PI(3)P and PI(3,5)P₂ are
155 enriched in early and late endosomes, respectively, and participate in their formation
156 [reviewed in ⁵⁵⁻⁵⁹]. In conventional endocytosis, EEA1 is recruited to early endosomes
157 through interactions with Rab5 and PI(3)P ⁶⁰⁻⁶². The latter is produced by Vps34, a PI3-
158 kinase that is also recruited by Rab5. We therefore, used pan-PI3K inhibitors
159 (wortmannin and LY294002) and assessed the colocalization between selected
160 endosomal material and EEA1 or Lamp1. Our data show that, in the presence of
161 LY294002, transferrin and dextran endosomal maturation and progression was halted,
162 consistent with observations reported in the literature ^{14,63} (Figure 2A and S2D).
163 However, colocalization between CPPs and EEA1 or Lamp1 was not affected (Figure
164 2A). Furthermore, depletion of PI(3,4)P₂, enriched on the plasma membrane ⁵⁹, blocks

165 the maturation of clathrin-coated vesicles prior to their fission from the plasma
166 membrane ⁶⁴, and prevents macropinosome closure ^{65,66}. As these events precede
167 Rab5 recruitment, we next determined whether the presence of wortmannin, which at
168 high micromolar concentrations, besides PI(3)P depletion, additionally inhibits PI4-
169 kinases ^{67,68} and leads to depletion of PI(3,4,5)P₃ ⁶⁹ and PI(3,4)P₂ ^{70,71}, would have an
170 effect on CPP endocytosis. Indeed, wortmannin treatment almost fully inhibited the
171 endocytosis of transferrin and dextran, as opposed to the tested CPPs, where the
172 number of vesicles was either only marginally reduced (R9) or remained unchanged
173 (TAT) (Figure 2B).

174 Even though previous studies have shown some contradictory results of CPP
175 internalization in the presence of the endocytic inhibitors used in this study [decreased
176 uptake ^{46,72-74}, no effect ^{45,74-76}, increased uptake ⁷⁷], our data clearly indicate that CPPs
177 enter cells through an uncharacterized endocytic pathway, which differs from classical
178 endocytosis already at the stage of endocytic vesicle formation.

179

180 **Rab14 is required for the maturation of CPP-containing endosomes**

181 All previously characterized endocytic pathways appear to converge to Rab5-positive
182 vesicles ^{1,2,78-87}. In the absence of Rab5, the number of maturing endocytic vesicles is
183 decreased and endocytosis is halted ⁶². To determine whether EEA1 recruitment to
184 CPP-positive vesicles occurs in the absence of Rab5, we took advantage of a knockout
185 Rab library in MDCK cells, which consists of single and multiple knockouts (>50 cell
186 lines) targeting either different protein isoforms or multiple Rab proteins simultaneously
187 ⁸⁸. This library includes a Rab5 conditional knockout cell line, where Rab5A, B and C
188 isoforms have been knocked out and replaced by a Rab5A version that can be
189 degraded through auxin-induced ubiquitination upon addition of indole-3-acetic acid

190 (IAA)⁸⁹ (Y. Homma et al., manuscript in preparation) (Figure S3A). The recruitment of
191 EEA1 (15 minutes post incubation), as well as Lamp1 (30 minutes post incubation) to
192 TAT-containing vesicles was not affected by the absence of Rab5 (Figure 3 and S3B).
193 Furthermore, inhibiting Rab5 with dominant-negative constructs (Rab5A S34N, Rab5B
194 S34N or Rab5C S35N) in HeLa cells, while reducing the percentage of EEA1-positive
195 transferrin- and dextran-containing vesicles, as expected, had no significant effect on
196 the percentage of EEA1-positive (Figure S3C-D) or Lamp1-positive (Figure S3E) CPP-
197 containing endosomes. This set of data argues against a role of Rab5 isoforms in the
198 maturation of CPP-containing endosomes and for EEA1 recruitment on these
199 endosomes.

200 Using a candidate-based approach and the Blastp database, we identified a subset of
201 candidate proteins with amino acid sequence similarity to Rab5. Using GPS Protein
202 (<http://gpsprot.org/navigator.php?q=84111>), a database of protein-protein interactions,
203 we restricted the pool of these Rab5-like proteins to those that have the potential to
204 interact with EEA1. We identified three top candidates using this approach: Rab14,
205 Rab22 and Rab31 (also known as Rab22B). Additionally, Rab21 bears sequence
206 similarity to Rab5 and colocalizes with early endosomal markers (Rab5 and EEA1⁹⁰⁻
207 ⁹²). Rab14 colocalizes with early endosomal markers⁹³⁻⁹⁵, but not late endosomal
208 markers^{93,95,96} (Figure S4) and has so far been shown to be involved in endosomal
209 recycling⁹⁷, endosome-endosome fusion, and MHC class I cross presentation⁹⁶.
210 Rab14 and Rab22 are both involved in endosome to Golgi trafficking^{93,95,98}, and Rab31
211 plays a role in Golgi-endosome directional transport⁹⁹. Rab22 can directly interact with
212 EEA1^{98,100}, supporting the hypothesis that it could function in a manner similar to
213 Rab5. Our data showed that Rab14, Rab21 and Rab22 colocalize relatively frequently
214 (as opposed to Rab31) with transferrin^{93,94}, and CPPs, as well as to a lesser extent

215 with dextran (Figure S5A). Furthermore, dominant-negative versions of these proteins
216 (Rab14 S25N, Rab14 N124I, Rab21 T31N, Rab22 S19N) were used to assess the role
217 of the respective Rab proteins in CPP-containing vesicle maturation. Figure S5 shows
218 diminished colocalization between CPPs and EEA1 in cells expressing Rab14 S25N
219 and Rab14 N124I, but not in cells expressing the other dominant negative mutants.
220 Rab14 is therefore a strong candidate that can substitute for Rab5 function in the
221 recruitment of EEA1 to maturing CPP-containing endosomes. The colocalization
222 between transferrin, as well as dextran and EEA1 appears not to be affected in the
223 Rab14 dominant negative background (Figure S5B). Similarly, earlier work has
224 reported that EEA1 colocalization with mannose receptors ⁹⁶ or with EGF ⁹⁵ is not
225 affected when Rab14 is depleted in cells.

226 We then used a MDCK-II comprehensive Rab knock-out library to test whether
227 colocalization between CPPs and EEA1 or Lamp1 is affected by the depletion of
228 various Rab protein isoforms at 15- and 30-minutes post incubation. The obtained data
229 further support the involvement of Rab14 in the maturation of CPP-containing vesicles
230 (Figure 3). Surprisingly, none of the other tested single or multiple Rab knockouts had
231 an effect on EEA1 or Lamp1 recruitment to CPP-positive endosomes (Figure 3). Taken
232 together our data demonstrates that ensuing their uptake by cells, CPPs follow a Rab5-
233 independent, Rab14-dependent endocytic route.

234

235 **Homeoproteins and polyamines use the same endocytic pathway as CPPs**

236 Homeoproteins (HPs) are a family of transcription factors involved in multiple biological
237 processes ¹⁰¹⁻¹⁰⁴. Additionally, HPs, such as Engrailed 2 and OTX2, exhibit therapeutic
238 properties ¹⁰⁵⁻¹¹⁰. The vast majority of HPs contain a conserved 60 amino-acids domain

239 called the homeodomain (HD) that carries HP internalization and secretion motifs.
240 Interestingly, the HP internalization motifs bear CPP sequences ^{101,103}. We therefore
241 hypothesized that HDs could be endocytosed similarly as CPPs. Through
242 colocalization experiments we determined that there is indeed colocalization between
243 HD-containing endosomes and the EEA1 or Lamp1 markers, and that their
244 colocalization with Rab5A or Rab7A is only marginal (Figure 4A, left). As for CPPs,
245 EEA1 and Lamp1 recruitment to HD-positive endosomes was significantly reduced in
246 cells lacking Rab14 (Figure 4B, left). This indicates that HDs follow a Rab5-
247 independent, Rab14-dependent endosomal pathway. Polyamines are small signaling
248 molecules involved in numerous cellular processes (gene regulation, cell proliferation,
249 cell survival and cell death) ¹¹¹⁻¹¹⁵. In mammalian cells polyamines enter cells through
250 endocytosis ¹¹⁶⁻¹¹⁹, and possibly also through a polyamine specific transporter ¹¹⁷.
251 Polyamine-containing vesicles mature to Lamp1-containing acidic endosomes and are
252 then exported into the cytosol ¹¹⁹. The mechanism of polyamines endocytosis has not
253 been described at the molecular level. Similarly, to CPPs and HDs, polyamine-
254 containing vesicles colocalized only marginally with Rab5A and Rab7A markers and
255 their maturation down to Lamp1-containing endosomes was Rab14-dependent (Figure
256 4A-B, right and S6). These data indicate that physiological molecules such as
257 polyamines, and by extension homeoproteins if they behave like their homeodomains,
258 do not enter cells through the classical Rab5-dependent endocytic route but via a
259 Rab14-dependent pathway.

260

261 **Discussion**

262 We have characterized a previously undescribed Rab5-independent, Rab14-
263 dependent endosomal pathway. In this pathway, EEA1 is recruited to early endosomes
264 in the absence of Rab5 (Figures 1, 3 and S3) and endosomal maturation requires
265 Rab14 (Figures 3 and S5). This pathway appears to differ from previously described
266 endocytosis already at the early stages of vesicle formation (Figure 2). We showed
267 that synthetic molecules as CPP, as well as physiological molecules such as
268 polyamines take advantage of the Rab5-independent, Rab14-dependent pathway to
269 enter cells and reach lysosomes.

270 The molecules that we have found to be endocytosed via the Rab14-dependent
271 pathway are characterized by their strong cationic nature. As Rab14 is expressed in
272 most tissues (according to Protein Atlas and CCLE database) and seems to be present
273 in the last eukaryote common ancestor^{97,120}, it is possible that Rab14 is involved in a
274 primordial endosomal pathway taken by cationic cargos. Whether this pathway is used
275 by other types of cargos can now be assessed functionally in cells in which Rab14 is
276 inactivated or invalidated.

277 Besides Rab14, no other Rab proteins could be evidenced to play a role in maturation
278 of the endocytic pathway taken by CPPs, HDs, or polyamines. In particular, we did not
279 find a Rab7 homolog that would be required for the acquisition of the Lamp1 marker in
280 this pathway. Either Rab14 is the sole Rab necessary for cargo progression along the
281 endocytic pathway used by CPPs, HDs, or polyamines or there is an as yet unknown
282 Rab isoform that is redundant with Rab7 in this pathway. Because there is only
283 marginal colocalization between Rab14 and Lamp1^{93,96} (Figure S4), the possibility that
284 Rab14 plays a dual role in the recruitment of EEA1 and Lamp1 is unlikely. Based on

285 phylogeny and clustering analysis ^{95,97,120}, Rab7 is most closely related to Rab9.
286 However, cells lacking both Rab7 and Rab9 were not compromised in their ability to
287 move cationic cargos along the Rab14-dependent pathway all the way down to Lamp1-
288 containing vesicles (Figure 3). The Rab isoform that is redundant with Rab7, if it exists,
289 remains therefore to be discovered.

290 There was minimal colocalization between CPP-, HP- or polyamine-containing
291 endosomes and the Rab5 and Rab7 endosomal markers. This marginal entry could
292 correspond to non-selective bulk liquid uptake, as it occurs during macropinocytosis
293 ¹²¹. Alternatively, a small fraction of these cargos may enter the Rab5-dependent
294 endosomal pathway as previously reported for CPPs ^{16,18-23}.

295 There have been earlier circumstantial indications of the existence of a Rab5-
296 independent pathway specifically in the context of viral infections, as well as trafficking
297 to yeast vacuole ^{122,123}. It has been shown that some viruses use unconventional
298 endocytosis, such as Herpes Simplex Virus 1 ¹²⁴, SARS ¹²⁵, Lassa virus, the Amr53b
299 and We54 strains of LCMV (lymphocytic choriomeningitis virus) ¹²⁶⁻¹²⁹, Lujo virus ^{130,131}
300 and some influenza A strains ¹³² that appear to skip the early Rab5-positive
301 endosomes. Rab14 also appears to be involved in viral trafficking, more specifically in
302 the endocytosis of Ebola virus matrix protein VP40 ¹³³. Additionally, Rab14 depletion
303 delayed *Candida albicans*- containing phagosome maturation to Lamp1, even though
304 Rab5 and Rab7 markers were still present during the maturation process ¹³⁴. Possibly,
305 the Rab5-independent, Rab14-dependent endosomal pathway is used by some
306 pathogens to infect cells. Therefore, our findings may not only concern the
307 physiological delivery of cationic cargo into cells, but could also be relevant for the
308 search of anti-viral or antimicrobial drugs.

309 **Author contributions**

310 Conception and design of study: ET and CW

311 Acquisition of data: ET

312 Analysis and/or interpretation of data: ET, YH, MF and CW

313 Funding acquisition: YH, MF and CW

314 Resources: MF and CW

315 Drafting the manuscript: ET and CW

316 Revising the manuscript and approval of the submitted version: all authors

317

318 **Acknowledgements**

319 The laboratory of YH is supported by Grant-in-Aid for Young Scientists from the
320 Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan
321 (grant number 20K15739). The laboratory of MF is supported by Grant-in-Aid for
322 Scientific Research(B) from the MEXT (grant number 19H03220) and Japan Science
323 and Technology Agency (JST) CREST (grant number JPMJCR17H4). We are thankful
324 to the Cellular Imaging Facility and Bioinformatics Competence Centre at the
325 University of Lausanne for the resources provided and their technical help.

326

327 **Competing interests**

328 Authors declare no competing financial and non-financial interests.

329

330 **Materials & Correspondence**

331 Correspondence and requests for materials should be addressed to CW.

332

333 **MATERIAL AVAILABILITY**

334 Further information and requests for resources and reagents should be directed to and
335 will be fulfilled by Christian Widmann (christian.widmann@unil.ch). Plasmids
336 generated in this study will be deposited to Addgene. This study did not generate any
337 new unique reagents.

338

339 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

340 **Cell lines**

341 All cell lines were cultured in 5% CO₂ at 37°C. HeLa (ATCC: CCL-2) cells were cultured
342 in RPMI media (Thermo Fisher, Cat# 61870044) supplemented with 10% heat-
343 inactivated fetal bovine serum (FBS; Thermo Fisher, Cat# 10270-106). MDCK-II
344 parental and knock-out cell lines⁹⁹ (available from RIKEN BioResource Research
345 Center Cell Bank (<https://cell.brc.riken.jp/en>); Cat#: RCB5099–RCB5148) were
346 cultured in DMEM (Thermo Fisher, Cat# 10566016). MDCK-II Rab5 knock-out and
347 degron-Rab5A-expressing cell line will be described elsewhere (Homma et al.,
348 manuscript in preparation).

349

350 **REAGENTS**

351 **Chemicals**

352 Live Hoechst 33342 (Sigma, Cat# CDS023389) was aliquoted and stored at -20°C.
353 AlexaFluor488-, AlexaFluor568-, AlexaFluor647-labeled human transferrin was
354 dissolved in PBS at 5 mg/ml and stored at 4°C (Thermo Fisher, Cat# T13342, T23365
355 and T23366). TMR-labelled 10,000 neutral dextran was dissolved in PBS at 10 mg/ml
356 and stored at -20°C (Thermo Fisher, Cat# D1816). AlexaFluor647-labeled and
357 biotinylated epidermal growth factor (EGF) was dissolved in water at 1 mg/ml,

358 aliquoted and stored at -20°C (Thermo Fisher Cat# E35351). EIPA (stock
359 concentration 10 mM), IPA3 (stock concentration 5 mM), ML7 (stock concentration 10
360 mM), CytoD (stock concentration 1 mM), Jas (stock concentration 1 mM) a kind gift
361 from Stefan Kunz laboratory, were dissolved in DMSO, aliquoted and stored at -20°C.
362 LY294002 was dissolved in DMSO at 20 mg/ml, aliquoted and stored at -20°C (Sigma
363 Aldrich, Cat# 440202). Wortmannin was aliquoted and stored at -20°C (Sigma Aldrich,
364 Cat# W1344). Indole-3-acetic acid (IAA) (Sigma-Aldrich, Cat# I2886) was dissolved in
365 ethanol, aliquoted and stored at -20°C. Doxycycline (Sigma-Aldrich, Cat# D3447) was
366 dissolved in DMSO, aliquoted and stored at -20°C.

367

368 **Antibodies**

369 The mouse monoclonal anti-EEA1, stored at -20°C (BD Transduction Laboratories,
370 Cat# 610457) and anti-Lamp1, stored at 4°C (BD Pharmingen, Cat# 555798)
371 antibodies were used in immunofluorescence experiments. Donkey polyclonal anti-
372 mouse Cy3 secondary antibody was aliquoted and stored at -20°C in glycerol (Jackson
373 ImmunoResearch, Cat# 715-165-150). Phospho-AKT (Ser473) rabbit polyclonal
374 antibody was stored at -20°C (Cell signaling, Cat# 92715) and was used for western
375 blotting. Anti-Rab5C antiserum, which can recognize all three Rab5 isoforms ¹³⁵, was
376 stored at -20°C.

377

378 **METHOD DETAILS**

379 **Confocal microscopy**

380 Confocal microscopy experiments were done on live cells. Cells were seeded onto
381 glass bottom culture dishes (MatTek, corporation Cat# P35G-1.5-14-C) and treated as
382 described in the Figures. For nuclear staining, 10 µg/ml live Hoechst 33342 (Molecular

383 probes, Cat# H21492) was added in the culture medium 5 minutes before washing
384 cells twice with media. After washing, cells were examined at the indicated time point
385 with a plan Aplanachromat 63x oil immersion objective mounted on a Zeiss LSM 780 laser
386 scanning fluorescence confocal microscope equipped with gallium arsenide phosphide
387 detectors and three lasers (a 405 nm diode laser, a 458-476-488-514 nm argon laser,
388 and a 561 nm diode-pumped solid-state laser). Cell images were acquired at a focal
389 plane near the middle of the cell making sure that nuclei were visible. Experiments at
390 20°C were done using an incubation chamber set at 20°C, 5% CO₂ and visualized with
391 a Zeiss LSM710 Quasar laser scanning fluorescence confocal microscope equipped
392 with either Neofluar 63x, 1.2 numerical aperture (NA) or plan Neofluar 100x, 1.3 NA
393 plan oil immersion objective (and the same lasers as above).

394

395 **Colocalization**

396 Colocalization assessment between endocytosed material and a given endosomal
397 marker was performed on confocal images by visual assessment, switching back and
398 forth between the color channels. The samples were randomized to blind the
399 experimentators from the nature of the samples they were analyzing. The
400 randomization script is available at <https://github.com/BICC-UNIL-EPFL/randomizer>.
401 The visual quantitation was validated by Mander's coefficient calculation performed on
402 the same samples using the JaCoP plugin in ImageJ. Examples of colocalization
403 quantitation analysis is shown in Figure S1A.

404

405 **Immunofluorescence**

406 Immunofluorescence experiments for the localization of endogenous and ectopically
407 expressed EEA1 and Lamp1 endosomal markers was performed as described ⁵⁷.

408 Briefly, cells were plated on poly L-lysine-coated coverslips and fixed with 4%
409 paraformaldehyde for 20 minutes at room temperature at the indicated time points after
410 treatment. Following a 5-minute permeabilization at room temperature in PBS, 0.25%
411 triton X100, the samples were blocked for 20 minutes at room temperature in PBS, 3%
412 BSA. Incubation with primary antibodies was done for two hours at room temperature
413 in PBS, 1% BSA. The cells were then incubated for 45 minutes at room temperature
414 with Cy3-labelled secondary antibodies in the same buffers as above. Coverslips were
415 finally incubated 5 minutes with PBS, 10 μ g/ml Hoechst. Three PBS washes were done
416 between each incubation steps. Coverslips were mounted in Fluoromount-G
417 (cBioscience, Cat# 00-4958-02). Samples were visualized with a Zeiss LSM780
418 confocal microscope.

419

420 **Transient transfection**

421 Calcium phosphate based transfection of HeLa cells was performed as previously
422 described¹³⁶. Briefly, cells were plated overnight in DMEM (Invitrogen, Cat# 61965)
423 medium supplemented with 10% heat-inactivated FBS (Invitrogen, Cat# 10270-106),
424 2.5 μ g of total plasmid DNA of interest was diluted in water, CaCl_2 was added and the
425 mixture was incubated in presence of HEPES 2x for 60 seconds before adding the
426 total mixture drop by drop to the cells. Media was changed 10 hours after.

427 Transient transfection in MDCK cells was done with Lipofectamin 2000 reagent
428 according to supplier's instructions (Thermo Fisher, Cat# 11668030).

429

430 **PI3-kinase inhibitors**

431 For the colocalization experiments, cells ectopically expressing GFP-EEA1, were
432 preincubated in the presence or in the absence of PI3K inhibitors 25 μ M LY294002 or

433 10 μ M wortmannin for 30 minutes, then Alexa548-transferrin or TMR-CPP were added
434 to the cells for 5 minutes. Cells were washed on ice with RPMI, 10% FBS and
435 incubated in same media in the presence of the inhibitors. Cells were visualized with
436 LSM780 confocal microscope at the indicated time points. Colocalization between
437 fluorescent cargo and EEA1 was visually quantitated. For western blotting experiments
438 phosphorylated AKT was used as a proxy of PI3K activity. To stimulate
439 phosphorylation, cells were incubated in serum-free medium for one hour. Medium was
440 then changed to RPMI, 10% serum and cells were incubated for 20 minutes with 25
441 μ M LY294002. Phosphorylated AKT was detected using rabbit anti-phosphoAKT
442 antibody (Cell signaling, Cat# 92715).

443

444 **Macropinocytosis inhibition**

445 Cells ectopically expressing GFP-EEA1 were starved overnight to stimulate
446 macropinocytosis. Media was then changed to RPMI containing 10% FBS and cells
447 were preincubated for 30 minutes with the indicated macropinocytosis inhibitors (kind
448 gift from Dr. Stephan Kunz lab). Cells were pulsed for 5 minutes with TexasRed-
449 dextran or TMR-TAT-RasGAP₃₁₇₋₃₂₆, washed and visualized under confocal
450 microscope in RPMI, 10% FBS in the presence of macropinocytosis inhibitors.

451

452 **Plasmid constructs**

453 The RFP-hRab5A.dn3 (#921) plasmid encoding RFP-labeled version of human Rab5A
454 protein was from Addgene (Cat# 14437). The mCh-hRab7A (#922) plasmid encoding
455 mCherry-labeled version of human Rab7A protein was from Addgene (Cat# 61804).
456 GFP-hRab5A.dn3 (#966), GFP-hRab7A.dn3 (#968), GFP-DynI.dn3 (#963) plasmid
457 encoding GFP-labeled versions of the indicated human proteins, as well as dominant

458 negative isoforms of the following proteins GFP-hRab5A(S34N).dn3 (#961), GFP-
459 Rab7A(T22N).dn3 (#969), GFP-Dynl(K44A).dn3 (#964) were a kind gift from Stefan
460 Kunz laboratory. mCh-hRab5(S34N) (#933), plasmid encoding a mCherry-labeled
461 dominant negative mutant version of human Rab5A was from Addgene (Cat# 35139).
462 GFP-hRab5B.dn3 (#1008) plasmid encoding GFP-labeled wild-type version of human
463 Rab5B isoform was from Addgene (Cat# 61802). GFP-hRab5B(S34N) (#1067)
464 plasmid encoding GFP-labeled dominant negative mutant version of human Rab5B
465 isoform was introduced to plasmid #1008 using Q5 Site-Directed Mutagenesis kit (NEB,
466 Cat# E0554S) according to manufacturer's instructions using forward primer #1554
467 (AGTGGGAAAGaacAGCCTGGTATTAC) and reverse primer #1555
468 (GCAGATTCTCCCAGCAGG). GFP-Rab5C.dn3 (#1074) plasmid encoding GFP-
469 labeled version of human Rab5C isoform was from Genescript (Cat# OHu09753C).
470 CFP-hRab5C(S35N).dn3 (#1006) encoding Cerulean-labeled dominant negative
471 mutant version of human Rab5C isoform was from Addgene (Cat# 11504). GFP-
472 hEEA1 (#970) and hLamp1-GFP.dn3 (#971) encoding GFP-labeled version of human
473 EEA1 and Lamp1, respectively were from Addgene (Cat# 42307 and 34831). BFP-
474 EEA1 (#1009) plasmid was generated by subcloning GFP-hEEA1 (#970) into a BFP-
475 hRab7A-Myc backbone (#1005, Addgene Cat# 79803) through ligation of both
476 plasmids after digestion with BamHI (NEB, Cat# R313614) and BspEI (NEB, Cat#
477 R0540S). hLamp1-BFP (#1016) plasmid encoding BFP-labeled version of human
478 Lamp1 protein was from Addgene (Cat# 98828). GFP-hRab14.dn3 (#1017), GFP-
479 hRab21.dn3 (#1023), GFP-hRab22.dn3 (#1018) and GFP-hRab31.dn3 (#1019)
480 plasmids encoding GFP-labeled versions of the indicated human wild-type proteins
481 were from Addgene (Cat# 49549, 83421, 49600 and 49610, respectively). GFP-
482 hRab14(S25N).dn3 (#1037) and GFP-hRab14(N124I).dn3 (#1038) plasmids encoding

483 GFP-labeled versions of dominant negative Rab14 mutant were from Addgene (Cat#
484 49594 and 49593). GFP-hRab21(T31N) (#1039) plasmid encoding GFP-labeled
485 version of dominant negative Rab21 mutant was from Addgene (Cat# 83423). GFP-
486 hRab22(S19N) (#1068) was generated using Q5 Site-Directed Mutagenesis kit (NEB,
487 Cat# E0554S) according to manufacturer's instructions with forward primer #1556
488 (TGTAGGTAAAaacAGTATTGTGTGGCGG) and reverse primer #1557
489 (CCTGTATCCCCGAGCAGA) on plasmid #1018 that encodes the wild-type isoform of
490 human Rab22 protein.

491

492 **Peptides**

493 TAT-RasGAP₃₁₇₋₃₂₆ is a retro-inverso peptide (i.e. synthesized with D-amino-acids in
494 the opposite direction compared to the natural sequence) labeled or not with FITC or
495 TMR. The TAT moiety corresponds to amino-acids 48–57 of the HIV TAT protein
496 (RRRQRRKRG) and the RasGAP₃₁₇₋₃₂₆ moiety corresponds to amino-acids from 317
497 to 326 of the human RasGAP protein (DTRLNTVMMW). These two moieties are
498 separated by two glycine linker residues in the TAT-Ras-GAP₃₁₇₋₃₂₆ peptide. FITC- or
499 TMR-bound peptides without cargo: TAT, MAP (KLALKLALKALKALKLA), Penetratin
500 (RQIKWFQNRMRMKWKK), Transportan (GWTLNSAGYLLGKINLKALAALAKKIL), R9
501 (RRRRRRRRR), were synthesized in retro-inverso conformation. FITC-labeled
502 homeodomain: OTX2-HD (QRRERTTFTRAQLDVLEALFAKTRYPDIFMREEVALKINL
503 PESRVQVWFKNRRRAKCRQQQ). All peptides were synthesized by SBS Genetech,
504 China and resuspended to 1 mM in water.

505

506 **Polyamine labeling**

507 Spermine fluorescent labeling with CF405M or CF594 dyes was performed using a
508 Mix-n-Stain Small Ligand Labeling Kit (Biotium, Cat# 92362 and 92352, respectively)
509 according to manufacturer's instructions. The labeling efficiency was assessed by
510 reverse-phase HPLC at Protein and Peptide Chemistry Facility at University of
511 Lausanne.

512

513 **Statistical analysis**

514 Statistical analysis was performed on non-normalized data, using GraphPad Prism 7.
515 All measurements were from biological replicates. Unless otherwise stated, the vertical
516 bars in the graph represent the standard deviation of mean from at least three
517 independent experiments.

518

519 **Data availability**

520 Image randomization script can be found at: [https://github.com/BICC-UNIL-](https://github.com/BICC-UNIL-EPFL/randomizer)
521 [EPFL/randomizer](https://github.com/BICC-UNIL-EPFL/randomizer).

522

523 **Figure legends**

524

525 **Figure 1. CPPs follow a Rab5-independent endocytic pathway.**

526 **(A-D)** HeLa KCNN4 knock-out cells ectopically expressing the fluorescently-tagged
527 early (Rab5A, Rab5B and EEA1) or late (Rab7 and Lamp1) endosomal markers were
528 incubated with 20 $\mu\text{g/ml}$ transferrin, 0.2 mg/ml dextran 10 kDa, 2 $\mu\text{g/ml}$ EGF or with 40
529 μM of CPPs linked or not to a cargo for 5 minutes, then washed and imaged at the
530 indicated time points by confocal microscopy (see Figure S1B for experimental setup).
531 All experiments were performed on live cells at 37°C unless indicated otherwise.

532 **(A)** Representative confocal images of HeLa KCNN4 knock-out cells, expressing GFP-
533 tagged endosomal markers, incubated with AlexaFluor568-transferrin or TMR-TAT.
534 Images were acquired at 5 or 30 minutes after the addition of endosomal material.
535 Scale bar: 10 μm .

536 **(B-C)** Quantitation of colocalization between the indicated fluorescent material and
537 fluorescently-tagged early and late endosomal markers. Colocalization analysis was
538 performed as described in Methods and Figure S1A. The data correspond to mean \pm
539 SD of three independent experiments. In panel B, the data obtained with R9 are shown,
540 for comparison, both on the top graphs and the bottom graphs. In panel C, cells were
541 incubated at 20°C to delay endosomal maturation.

542 **(D)** Representative confocal, Airyscan acquired, high-resolution images of cells
543 ectopically expressing GFP-EEA1 incubated with 40 μM TMR-TAT for 5 minutes. Scale
544 bar: 2 μm .

545

546 **Figure 2. CPP endocytosis does not require PI(3)P-kinase-like enzymes.**

547 **(A)** Colocalization quantitation between the indicated endosomal material and
548 endosomal markers in the presence or in the absence of LY294002, a pan-PI3-kinase
549 inhibitor. HeLa KCNN4 knock-out cells, ectopically expressing GFP-tagged EEA1 or
550 Lamp1, were incubated with 20 $\mu\text{g/ml}$ AlexaFluor568-Transferrin, 0.2 mg/ml TMR-
551 Dextran 10 kDa or 40 μM TMR-R9 for a pulse of 5 minutes. Cells were preincubated
552 or not for 30 minutes with 25 μM LY294002, which was still present during the full
553 duration of the experiment. The data correspond to mean \pm SD of three independent
554 experiments. The p-values were calculated based on area under the curve (AUC)
555 analysis followed by a t-test.

556 **(B)** Quantitation of the number of endosomal vesicles per cell in the presence or in the
557 absence of wortmannin, a pan-PI3-kinase inhibitor. HeLa KCNN4 knock-out cells were
558 incubated with 20 $\mu\text{g/ml}$ AlexaFluor568-Transferrin, 0.2 mg/ml TMR-Dextran 10 kDa
559 or 40 μM TMR-CPP for a pulse of 5 minutes. Cells were preincubated or not for 30
560 minutes with 10 μM wortmannin, which was still present during the full duration of the
561 experiment. The number of vesicles positive for the indicated endosomal material were
562 visually calculated based on confocal images, acquired in the middle of the cell. A
563 minimum of 150 cells were quantitated per condition. The results correspond to three
564 independent experiments. The p-values were calculated using paired t-test.

565

566 **Figure 3. CPP endosomal maturation is Rab14-dependent.**

567 Quantitation of colocalization between TMR-TAT and GFP-EEA1 (15 minutes, top) or
568 Lamp1-GFP (30 minutes, bottom) in a pulse chase experiment in MDCK-II wild-type
569 cells and the indicated Rab knock-outs. A minimum of 50 cells were quantitated per
570 condition. Statistical analysis was performed with ANOVA multiple comparison to wild-
571 type condition with Dunnett's correction. Only significant p-values are shown on the
572 Figure. Rab5-degron cells were treated with 1 $\mu\text{g/ml}$ doxycycline and 500 μM IAA for
573 48 hours to induce degradation of degron-tagged Rab5A in the Rab5B/C knockout cell
574 line.

575

576 **Figure 4. HDs and polyamines are following a Rab5-independent, Rab14- 577 dependent endocytic route.**

578 **(A)** Colocalization quantitation between endosomal markers and HD or polyamine.
579 HeLa KCNN4 knock-out cells, ectopically expressing the indicated endosomal
580 markers, were subjected to a 5-minute pulse incubation with fluorescently labelled
581 OTX2 HD (10 μM) or spermine (5 μM). Quantitation assessment was based on
582 confocal images. The results correspond to mean \pm SD of three independent
583 experiments.

584 **(B)** Colocalization quantitation between fluorescent versions of OTX2-HD (10 μM) or
585 spermine (5 μM) with EEA1 (top) or Lamp1 (bottom) in MDCK-II wild-type and the
586 indicated Rab knockouts. Cells were incubated for 5 minutes, then washed and
587 confocal images were acquired at 15- and 30-minutes post incubation for early and
588 late endosomal markers, respectively. A minimum of 50 cells were quantitated per

589 condition. Statistical analysis was performed with ANOVA multiple comparison to wild-
590 type condition with Dunett's correction.

591

592 **Figure S1. Colocalization quantitation and experimental setup.**

593 **(A)** Colocalization quantitation between fluorescently labeled endosomal material and
594 endocytic markers. Left: representative confocal images of HeLa KCNN4 knock-out
595 cells expressing GFP-Rab5A, in the presence of 20 ug/ml AlexaFluor568-Transferrin
596 for 5 minutes. Colocalization assessment between endocytosed material and a given
597 endosomal marker was performed on confocal images by visual assessment,
598 switching back and forth between the color channels. The samples were randomized
599 to blind the experimentators from the nature of the samples they were analyzing. The
600 images shown on the left are cropped regions of cell transfected with GFP-Rab5 and
601 incubated with AlexaFluor568-transferrin. The circles numbered 1 to 5 depict examples
602 of colocalization versus non-colocalization between Rab5 and transferrin. Scale bar:
603 10 μm . Graphs on the right-hand side: our visual quantitation (mean \pm SD of three
604 independent experiments performed on 165 cells per condition) was validated by
605 Mander's coefficient calculation performed on the same samples using the JaCoP
606 plugin in ImageJ (shown as box plots).

607 **(B)** Scheme of the pulse chase experiments used in the experiments depicted in the
608 figures. Cells were incubated five minutes with various fluorescent material, washed,
609 and the endosomal maturation followed overtime.

610 **(C)** Ectopic expression does not alter the subcellular location of endosomal markers.
611 Ectopic (top row) and endogenous (bottom row) location of EEA1 and Lamp1. Scale
612 bar: 10 μm .

613 **(D)** Quantitation of the colocalization between ectopic or endogenous EEA1 or Lamp1
614 with Alexa568-transferrin in live or fixed KCNN4 knock-out HeLa cells. The data
615 correspond to mean \pm SD of three independent experiments. The p-values were
616 calculated using ANOVA analysis with Dunett's correction based on AUC values from
617 fixed samples compared to live samples.

618 **(E)** Colocalization quantitation of the indicated FITC-CPPs with TMR-R9. The data
619 correspond to the mean \pm SD of three independent experiments.

620 **(F)** Colocalization between TAT-RasGAP₃₁₇₋₃₂₆ (40 μM) and GFP-tagged Rab5, EEA1
621 or Rab7 in HeLa KCNN4 knock-out cell line. Cells were incubated in the continuous

622 presence of TAT-RasGAP₃₁₇₋₃₂₆. The data correspond to mean \pm SD of three
623 independent experiments.

624 **(G)** Colocalization between transferrin and Rab5 (top) or Rab7 (bottom) in the
625 presence or in the absence of 40 μ M TAT-RasGAP₃₁₇₋₃₂₆. The data correspond to
626 mean \pm SD of three independent experiments. The p-values were calculated based on
627 AUC analysis.

628 **(H)** Colocalization quantitation between ectopically expressed BFP-EEA1 and Lamp1-
629 GFP in the presence or in the absence of 40 μ M TAT-RasGAP₃₁₇₋₃₂₆. The data
630 correspond to mean \pm SD of three independent experiments.

631

632 **Figure S2. Endosomal vesicle formation inhibitors do not affect CPP uptake.**

633 **(A)** Representative confocal images of HeLa KCNN4 knock-out cells preincubated or
634 not with the indicated inhibitors for 30 minutes prior to the addition of 0.2 mg/ml TMR-
635 Dextran 10 kDa or 40 μ M TMR-TAT-RasGAP₃₁₇₋₃₂₆ for a 5-minute pulse. Confocal
636 images were acquired at 5, 30 and 60 minutes after the addition of endosomal material.
637 The inhibitors were present throughout the full duration of the experiment.

638 **(B)** Total cell fluorescence quantitation based on images acquired in panel A. Results
639 correspond to mean \pm SD of three independent experiments (n>150 cells per
640 condition).

641 **(C)** Representative confocal images of HeLa KCNN4 knock-out cells ectopically
642 expressing wild-type (Dyml WT) or dominant negative (Dyml K44A) version of dynamin
643 I. Cells were incubated with 20 μ g/ml AlexaFluor568-transferrin or 40 μ M TAT-
644 RasGAP₃₁₇₋₃₂₆. Cell nuclei were labeled with live Hoechst. White arrows point to cells
645 positively transfected with GFP-dynamin constructs and yellow arrows indicate non-
646 transfected cells. Images were acquired at 15 minutes post incubation with the cargos.

647 **(D)** Left panel: red Ponceau S stained membrane, right panel: phospho-AKT antibody
648 signal detection. HeLa KCNN4 knock-out cells incubated in the presence or in the
649 absence of 25 μ M pan-PI3-kinase inhibitor, LY294002. To stimulate AKT
650 phosphorylation cells were preincubated in a serum-free media for one hour.
651 Phosphorylated AKT was used as a proxy for PI3-kinase activity.

652

653 **Figure S3. CPP endocytosis is Rab5-independent.**

654 **(A)** Western blot-mediated Rab5 detection in MDCK-II wild-type or Rab5-degron cell
655 lysates incubated in the presence of 1 $\mu\text{g/ml}$ doxycycline and 500 μM IAA for the
656 indicated periods of time to induce degradation of Rab5A.

657 **(B)** Colocalization of TAT-containing vesicles with the indicated endosomal markers.
658 MDCK-II wild-type cells were incubated with 40 μM TMR-TAT for 5-minute pulse.

659 **(C)** Representative confocal images of cells analyzed in panel D-E in HeLa KCNN4
660 knockout cells.

661 **(D-E)** Colocalization quantitation of transferrin, dextran, and the indicated CPP with
662 EEA1 (panel D) or Lamp1 (panel E) in cells transfected with the indicated Rab5
663 dominant negative constructs in HeLa KCNN4 knockout cells in a pulse experiment
664 setting (see Figure S1B). The data correspond to mean \pm SD of three independent
665 experiments. Statistical analysis was performed using two-tailed t-test based on AUC
666 values. The p-values correspond to the comparison between the cells within the same
667 population transfected or not with the dominant negative constructs.

668

669 **Figure S4. Limited colocalization between Rab14 and Lamp1.**

670 **(A)** Representative confocal images of HeLa KCNN4 knockout cells ectopically
671 expressing GFP-Rab14 and Lamp1-BFP that were incubated for 5 minutes with 20
672 $\mu\text{g/ml}$ AlexaFluor647-Transferrin or 40 μM TMR-TAT. Images were acquired at 30
673 minutes post-incubation with endosomal cargo. Scale bar: 10 μm .

674 **(B)** Colocalization quantitation of Rab14 with Lamp1 from the experiment in panel A.
675 A minimum of 50 cells were quantitated per condition.

676

677 **Figure S5. Rab14 dominant negative mutants block the maturation of CPP-** 678 **containing endosomes.**

679 **(A)** Colocalization quantitation between the indicated endocytosed material and the
680 indicated GFP-labeled Rab proteins ectopically expressed in HeLa KCNN4 knockout
681 cells. The results correspond to mean \pm SD of three independent experiments.

682 **(B)** Colocalization quantitation between the indicated endocytosed material and EEA1
683 in cells transfected with Rab14, Rab21 or Rab22 dominant negative constructs. The
684 data correspond to the mean \pm SD of three independent experiments. Statistical
685 analysis was performed using ANOVA test with Dunnett's correction, based on AUC

686 values. The p-values correspond to the comparison between the cells within the same
687 population transfected or not with the dominant negative constructs.

688

689 **Figure S6. Spermine follows a Rab5-independent, Rab14-dependent endosomal**
690 **maturation.**

691 **(A)** Colocalization between 5 μ M spermine with EEA1 (top) or Lamp1 (bottom) in the
692 Rab5A dominant negative background. HeLa KCNN4 knockout cells were incubated
693 for 5-minute pulse with endosomal cargo. The results correspond to mean \pm SD of
694 three independent experiments. Statistical analysis was performed using two-tailed t-
695 test based on AUC values. The p-values correspond to the comparison between the
696 cells within the same population transfected or not with the dominant negative
697 constructs.

698 **(B)** Colocalization between 5 μ M spermine with EEA1 (top) or Lamp1 (bottom) in HeLa
699 KCNN4 knockout cells expressing Rab14 dominant negative mutants. The cells were
700 exposed to the cargos during a 5-minute pulse. The results correspond to mean \pm SD
701 of three independent experiments. Statistical analysis was performed using ANOVA
702 test with Dunnett's correction, based on AUC values. The p-values correspond to the
703 comparison between the cells within the same population transfected or not with the
704 dominant negative constructs.

705

706

707

708 References

- 709 1 Johannes, L., Parton, R. G., Bassereau, P. & Mayor, S. Building endocytic pits without clathrin.
710 *Nat Rev Mol Cell Biol* **16**, 311-321, doi:10.1038/nrm3968 (2015).
- 711 2 Mercer, J., Schelhaas, M. & Helenius, A. Virus entry by endocytosis. *Annu Rev Biochem* **79**,
712 803-833, doi:10.1146/annurev-biochem-060208-104626 (2010).
- 713 3 Kaksonen, M. & Roux, A. Mechanisms of clathrin-mediated endocytosis. *Nat Rev Mol Cell Biol*
714 **19**, 313-326, doi:10.1038/nrm.2017.132 (2018).
- 715 4 Schmid, S. L., Sorkin, A. & Zerial, M. Endocytosis: Past, present, and future. *Cold Spring Harb*
716 *Perspect Biol* **6**, a022509, doi:10.1101/cshperspect.a022509 (2014).
- 717 5 Thottacherry, J. J., Sathe, M., Prabhakara, C. & Mayor, S. Spoiled for Choice: Diverse
718 Endocytic Pathways Function at the Cell Surface. *Annu Rev Cell Dev Biol* **35**, 55-84,
719 doi:10.1146/annurev-cellbio-100617-062710 (2019).
- 720 6 Takei, K. & Haucke, V. Clathrin-mediated endocytosis: membrane factors pull the trigger.
721 *Trends Cell Biol* **11**, 385-391, doi:10.1016/s0962-8924(01)02082-7 (2001).
- 722 7 Cocucci, E., Aguet, F., Boulant, S. & Kirchhausen, T. The first five seconds in the life of a
723 clathrin-coated pit. *Cell* **150**, 495-507, doi:10.1016/j.cell.2012.05.047 (2012).
- 724 8 Chen, Z. & Schmid, S. L. Evolving models for assembling and shaping clathrin-coated pits. *J*
725 *Cell Biol* **219**, doi:10.1083/jcb.202005126 (2020).
- 726 9 Gautreau, A., Oguievetskaia, K. & Ungermann, C. Function and regulation of the endosomal
727 fusion and fission machineries. *Cold Spring Harb Perspect Biol* **6**,
728 doi:10.1101/cshperspect.a016832 (2014).
- 729 10 Scott, C. C., Vacca, F. & Gruenberg, J. Endosome maturation, transport and functions. *Semin*
730 *Cell Dev Biol* **31**, 2-10, doi:10.1016/j.semcdb.2014.03.034 (2014).
- 731 11 Huotari, J. & Helenius, A. Endosome maturation. *EMBO J* **30**, 3481-3500,
732 doi:10.1038/emboj.2011.286 (2011).
- 733 12 Naslavsky, N. & Caplan, S. The enigmatic endosome - sorting the ins and outs of endocytic
734 trafficking. *J Cell Sci* **131**, doi:10.1242/jcs.216499 (2018).
- 735 13 Murray, D. H., Jahnel, M., Lauer, J., Avellaneda, M. J., Brouilly, N., Cezanne, A., Morales-
736 Navarrete, H., Perini, E. D., Ferguson, C., Lupas, A. N., Kalaidzidis, Y., Parton, R. G., Grill, S. W.
737 & Zerial, M. An endosomal tether undergoes an entropic collapse to bring vesicles together.
738 *Nature* **537**, 107-111, doi:10.1038/nature19326 (2016).
- 739 14 Jaber, N., Mohd-Naim, N., Wang, Z., DeLeon, J. L., Kim, S., Zhong, H., Sheshadri, N., Dou, Z.,
740 Edinger, A. L., Du, G., Braga, V. M. & Zong, W. X. Vps34 regulates Rab7 and late endocytic
741 trafficking through recruitment of the GTPase-activating protein Armus. *J Cell Sci* **129**, 4424-
742 4435, doi:10.1242/jcs.192260 (2016).
- 743 15 Langemeyer, L., Frohlich, F. & Ungermann, C. Rab GTPase Function in Endosome and
744 Lysosome Biogenesis. *Trends Cell Biol* **28**, 957-970, doi:10.1016/j.tcb.2018.06.007 (2018).
- 745 16 Guidotti, G., Brambilla, L. & Rossi, D. Cell-Penetrating Peptides: From Basic Research to
746 Clinics. *Trends Pharmacol Sci* **38**, 406-424, doi:10.1016/j.tips.2017.01.003 (2017).
- 747 17 Vasconcelos, L., Parn, K. & Langel, U. Therapeutic potential of cell-penetrating peptides. *Ther*
748 *Deliv* **4**, 573-591, doi:10.4155/tde.13.22 (2013).
- 749 18 Bechara, C. & Sagan, S. Cell-penetrating peptides: 20 years later, where do we stand? *FEBS*
750 *Lett* **587**, 1693-1702, doi:10.1016/j.febslet.2013.04.031 (2013).
- 751 19 Trabulo, S., Cardoso, A. L., Mano, M. & De Lima, M. C. Cell-Penetrating Peptides-Mechanisms
752 of Cellular Uptake and Generation of Delivery Systems. *Pharmaceuticals (Basel)* **3**, 961-993,
753 doi:10.3390/ph3040961 (2010).
- 754 20 Futaki, S., Hirose, H. & Nakase, I. Arginine-rich peptides: methods of translocation through
755 biological membranes. *Curr Pharm Des* **19**, 2863-2868 (2013).
- 756 21 Jones, A. T. & Sayers, E. J. Cell entry of cell penetrating peptides: tales of tails wagging dogs. *J*
757 *Control Release* **161**, 582-591, doi:10.1016/j.jconrel.2012.04.003 (2012).

- 758 22 Madani, F., Lindberg, S., Langel, U., Futaki, S. & Graslund, A. Mechanisms of cellular uptake of
759 cell-penetrating peptides. *J Biophys* **2011**, 414729, doi:10.1155/2011/414729 (2011).
- 760 23 Koren, E. & Torchilin, V. P. Cell-penetrating peptides: breaking through to the other side.
761 *Trends Mol Med* **18**, 385-393, doi:10.1016/j.molmed.2012.04.012 (2012).
- 762 24 Illien, F., Rodriguez, N., Amoura, M., Joliot, A., Pallerla, M., Cribier, S., Burlina, F. & Sagan, S.
763 Quantitative fluorescence spectroscopy and flow cytometry analyses of cell-penetrating
764 peptides internalization pathways: optimization, pitfalls, comparison with mass spectrometry
765 quantification. *Sci Rep* **6**, 36938, doi:10.1038/srep36938 (2016).
- 766 25 Mueller, J., Kretschmar, I., Volkmer, R. & Boisguerin, P. Comparison of cellular uptake using
767 22 CPPs in 4 different cell lines. *Bioconjug Chem* **19**, 2363-2374, doi:10.1021/bc800194e
768 (2008).
- 769 26 Xie, J., Bi, Y., Zhang, H., Dong, S., Teng, L., Lee, R. J. & Yang, Z. Cell-Penetrating Peptides in
770 Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical
771 Application. *Front Pharmacol* **11**, 697, doi:10.3389/fphar.2020.00697 (2020).
- 772 27 Ruseska, I. & Zimmer, A. Internalization mechanisms of cell-penetrating peptides. *Beilstein J*
773 *Nanotechnol* **11**, 101-123, doi:10.3762/bjnano.11.10 (2020).
- 774 28 Kristensen, M., Birch, D. & Morck Nielsen, H. Applications and Challenges for Use of Cell-
775 Penetrating Peptides as Delivery Vectors for Peptide and Protein Cargos. *Int J Mol Sci* **17**,
776 doi:10.3390/ijms17020185 (2016).
- 777 29 Raagel, H., Saalik, P. & Pooga, M. Peptide-mediated protein delivery-which pathways are
778 penetrable? *Biochim Biophys Acta* **1798**, 2240-2248, doi:10.1016/j.bbamem.2010.02.013
779 (2010).
- 780 30 Cleal, K., He, L., Watson, P. D. & Jones, A. T. Endocytosis, intracellular traffic and fate of cell
781 penetrating peptide based conjugates and nanoparticles. *Curr Pharm Des* **19**, 2878-2894,
782 doi:10.2174/13816128113199990297 (2013).
- 783 31 Futaki, S. & Nakase, I. Cell-Surface Interactions on Arginine-Rich Cell-Penetrating Peptides
784 Allow for Multiplex Modes of Internalization. *Acc Chem Res* **50**, 2449-2456,
785 doi:10.1021/acs.accounts.7b00221 (2017).
- 786 32 Trofimenko, E., Grasso, G., Heulot, M., Chevalier, N., Deriu, M. A., Dubuis, G., Arribat, Y.,
787 Serulla, M., Michel, S., Vantomme, G., Ory, F., Dam, L. C., Puyal, J., Amati, F., Lüthi, A.,
788 Danani, A. & Widmann, C. Genetic, cellular and structural characterization of the membrane
789 potential-dependent cell-penetrating peptide translocation pore. *bioRxiv*,
790 2020.2002.2025.963017, doi:10.1101/2020.02.25.963017 (2021).
- 791 33 Torriani, G., Trofimenko, E., Mayor, J., Fedeli, C., Moreno, H., Michel, S., Heulot, M.,
792 Chevalier, N., Zimmer, G., Shrestha, N., Plattet, P., Engler, O., Rothenberger, S., Widmann, C.
793 & Kunz, S. Identification of clotrimazole-derivatives as specific inhibitors of Arenavirus fusion.
794 *J Virol*, doi:10.1128/JVI.01744-18 (2019).
- 795 34 Annibaldi, A., Dousse, A., Martin, S., Tazi, J. & Widmann, C. Revisiting G3BP1 as a RasGAP
796 Binding Protein: Sensitization of Tumor Cells to Chemotherapy by the RasGAP 317-326
797 Sequence Does Not Involve G3BP1. *PLoS One* **6**, doi:ARTN e29024
798 DOI 10.1371/journal.pone.0029024 (2011).
- 799 35 Barras, D., Lorusso, G., Lhermitte, B., Viertl, D., Ruegg, C. & Widmann, C. Fragment N2, a
800 caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression. *Int J*
801 *Cancer* **135**, 242-247, doi:10.1002/ijc.28674 (2014).
- 802 36 Barras, D., Lorusso, G., Ruegg, C. & Widmann, C. Inhibition of cell migration and invasion
803 mediated by the TAT-RasGAP317-326 peptide requires the DLC1 tumor suppressor.
804 *Oncogene* **33**, 5163-5172, doi:10.1038/onc.2013.465 (2014).
- 805 37 Chevalier, N., Gross, N. & Widmann, C. Assessment of the chemosensitizing activity of TAT-
806 RasGAP317-326 in childhood cancers. *PLoS One* **10**, e0120487,
807 doi:10.1371/journal.pone.0120487 (2015).

- 808 38 Heulot, M., Chevalier, N., Puyal, J., Margue, C., Michel, S., Kreis, S., Kulms, D., Barras, D.,
809 Nahimana, A. & Widmann, C. The TAT-RasGAP317-326 anti-cancer peptide can kill in a
810 caspase-, apoptosis-, and necroptosis-independent manner. *Oncotarget* **7**, 64342-64359,
811 doi:10.18632/oncotarget.11841 (2016).
- 812 39 Heulot, M., Jacquier, N., Aeby, S., Le Roy, D., Roger, T., Trofimenko, E., Barras, D., Greub, G. &
813 Widmann, C. The Anticancer Peptide TAT-RasGAP317-326 Exerts Broad Antimicrobial
814 Activity. *Front Microbiol* **8**, 994, doi:10.3389/fmicb.2017.00994 (2017).
- 815 40 Michod, D., Annibaldi, A., Schaefer, S., Dapples, C., Rochat, B. & Widmann, C. Effect of
816 RasGAP N2 fragment-derived peptide on tumor growth in mice. *J Natl Cancer Inst* **101**, 828-
817 832, doi:10.1093/jnci/djp100 (2009).
- 818 41 Michod, D., Yang, J. Y., Chen, J., Bonny, C. & Widmann, C. A RasGAP-derived cell permeable
819 peptide potently enhances genotoxin-induced cytotoxicity in tumor cells. *Oncogene* **23**,
820 8971-8978, doi:10.1038/sj.onc.1207999 (2004).
- 821 42 Pittet, O., Petermann, D., Michod, D., Krueger, T., Cheng, C., Ris, H. B. & Widmann, C. Effect
822 of the TAT-RasGAP(317-326) peptide on apoptosis of human malignant mesothelioma cells
823 and fibroblasts exposed to meso-tetra-hydroxyphenyl-chlorin and light. *J Photochem*
824 *Photobiol B* **88**, 29-35, doi:10.1016/j.jphotobiol.2007.04.009 (2007).
- 825 43 Tsoutsou, P., Annibaldi, A., Viertl, D., Ollivier, J., Buchegger, F., Vozenin, M. C., Bourhis, J.,
826 Widmann, C. & Matzinger, O. TAT-RasGAP317-326 Enhances Radiosensitivity of Human
827 Carcinoma Cell Lines In Vitro and In Vivo through Promotion of Delayed Mitotic Cell Death.
828 *Radiat Res* **187**, 562-569, doi:10.1667/RR14509.1 (2017).
- 829 44 Serulla, M., Ichim, G., Stojceski, F., Grasso, G., Afonin, S., Heulot, M., Schober, T., Roth, R.,
830 Godefroy, C., Milhiet, P. E., Das, K., Garcia-Saez, A. J., Danani, A. & Widmann, C. TAT-
831 RasGAP317-326 kills cells by targeting inner-leaflet-enriched phospholipids. *Proc Natl Acad*
832 *Sci U S A*, doi:10.1073/pnas.2014108117 (2020).
- 833 45 Deshayes, S., Konate, K., Dussot, M., Chavey, B., Vaissiere, A., Van, T. N. N., Aldrian, G.,
834 Padari, K., Pooga, M., Vives, E. & Boisguerin, P. Deciphering the internalization mechanism of
835 WRAP:siRNA nanoparticles. *Biochim Biophys Acta Biomembr* **1862**, 183252,
836 doi:10.1016/j.bbamem.2020.183252 (2020).
- 837 46 Appelbaum, J. S., LaRoche, J. R., Smith, B. A., Balkin, D. M., Holub, J. M. & Schepartz, A.
838 Arginine topology controls escape of minimally cationic proteins from early endosomes to
839 the cytoplasm. *Chem Biol* **19**, 819-830, doi:10.1016/j.chembiol.2012.05.022 (2012).
- 840 47 Koivusalo, M., Welch, C., Hayashi, H., Scott, C. C., Kim, M., Alexander, T., Touret, N., Hahn, K.
841 M. & Grinstein, S. Amiloride inhibits macropinocytosis by lowering submembranous pH and
842 preventing Rac1 and Cdc42 signaling. *J Cell Biol* **188**, 547-563, doi:10.1083/jcb.200908086
843 (2010).
- 844 48 Viaud, J. & Peterson, J. R. An allosteric kinase inhibitor binds the p21-activated kinase
845 autoregulatory domain covalently. *Mol Cancer Ther* **8**, 2559-2565, doi:10.1158/1535-
846 7163.MCT-09-0102 (2009).
- 847 49 Dharmawardhane, S., Schurmann, A., Sells, M. A., Chernoff, J., Schmid, S. L. & Bokoch, G. M.
848 Regulation of macropinocytosis by p21-activated kinase-1. *Mol Biol Cell* **11**, 3341-3352,
849 doi:10.1091/mbc.11.10.3341 (2000).
- 850 50 McLAUCHLAN, H., ELLIOTT, M. & COHEN, P. The specificities of protein kinase inhibitors: an
851 update. *Biochemical Journal* **371**, 199-204, doi:10.1042/bj20021535 (2003).
- 852 51 Araki, N., Hatae, T., Furukawa, A. & Swanson, J. A. Phosphoinositide-3-kinase-independent
853 contractile activities associated with Fcγ-receptor-mediated phagocytosis and
854 macropinocytosis in macrophages. *Journal of Cell Science* **116**, 247-257,
855 doi:10.1242/jcs.00235 (2003).
- 856 52 Bubb, M. R., Senderowicz, A. M., Sausville, E. A., Duncan, K. L. & Korn, E. D. Jasplakinolide, a
857 cytotoxic natural product, induces actin polymerization and competitively inhibits the
858 binding of phalloidin to F-actin. *J Biol Chem* **269**, 14869-14871 (1994).

- 859 53 Sampath, P. & Pollard, T. D. Effects of cytochalasin, phalloidin, and pH on the elongation of
860 actin filaments. *Biochemistry* **30**, 1973-1980 (1991).
- 861 54 Fujimoto, L. M., Roth, R., Heuser, J. E. & Schmid, S. L. Actin Assembly Plays a Variable, but not
862 Obligatory Role in Receptor-Mediated Endocytosis. *Traffic* **1**, 161-171, doi:10.1034/j.1600-
863 0854.2000.010208.x (2000).
- 864 55 Wenk, M. R. & De Camilli, P. Protein-lipid interactions and phosphoinositide metabolism in
865 membrane traffic: insights from vesicle recycling in nerve terminals. *Proc Natl Acad Sci U S A*
866 **101**, 8262-8269, doi:10.1073/pnas.0401874101 (2004).
- 867 56 Campa, C. C., Franco, I. & Hirsch, E. PI3K-C2alpha: One enzyme for two products coupling
868 vesicle trafficking and signal transduction. *FEBS Lett* **589**, 1552-1558,
869 doi:10.1016/j.febslet.2015.05.001 (2015).
- 870 57 Bissig, C., Johnson, S. & Gruenberg, J. Studying lipids involved in the endosomal pathway.
871 *Methods Cell Biol* **108**, 19-46, doi:10.1016/B978-0-12-386487-1.00002-X (2012).
- 872 58 Miaczynska, M. & Zerial, M. Mosaic organization of the endocytic pathway. *Exp Cell Res* **272**,
873 8-14, doi:10.1006/excr.2001.5401 (2002).
- 874 59 Ramadani, F., Bolland, D. J., Garcon, F., Emery, J. L., Vanhaesebroeck, B., Corcoran, A. E. &
875 Okkenhaug, K. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell
876 receptor signaling and B cell development. *Sci Signal* **3**, ra60, doi:10.1126/scisignal.2001104
877 (2010).
- 878 60 Simonsen, A., Lippe, R., Christoforidis, S., Gaullier, J. M., Brech, A., Callaghan, J., Toh, B. H.,
879 Murphy, C., Zerial, M. & Stenmark, H. EEA1 links PI(3)K function to Rab5 regulation of
880 endosome fusion. *Nature* **394**, 494-498, doi:10.1038/28879 (1998).
- 881 61 McBride, H. M., Rybin, V., Murphy, C., Giner, A., Teasdale, R. & Zerial, M. Oligomeric
882 complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between
883 EEA1 and syntaxin 13. *Cell* **98**, 377-386 (1999).
- 884 62 Zeigerer, A., Gilleron, J., Bogorad, R. L., Marsico, G., Nonaka, H., Seifert, S., Epstein-Barash,
885 H., Kuchimanchi, S., Peng, C. G., Ruda, V. M., Del Conte-Zerial, P., Hengstler, J. G., Kalaidzidis,
886 Y., Koteliansky, V. & Zerial, M. Rab5 is necessary for the biogenesis of the endolysosomal
887 system in vivo. *Nature* **485**, 465-470, doi:10.1038/nature11133 (2012).
- 888 63 Fili, N., Calleja, V., Woscholski, R., Parker, P. J. & Larijani, B. Compartmental signal
889 modulation: Endosomal phosphatidylinositol 3-phosphate controls endosome morphology
890 and selective cargo sorting. *Proc Natl Acad Sci U S A* **103**, 15473-15478,
891 doi:10.1073/pnas.0607040103 (2006).
- 892 64 Posor, Y., Eichhorn-Gruenig, M., Puchkov, D., Schoneberg, J., Ullrich, A., Lampe, A., Muller, R.,
893 Zerbakhsh, S., Gulluni, F., Hirsch, E., Krauss, M., Schultz, C., Schmoranzer, J., Noe, F. &
894 Haucke, V. Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate.
895 *Nature* **499**, 233-237, doi:10.1038/nature12360 (2013).
- 896 65 Hasegawa, J., Tokuda, E., Tenno, T., Tsujita, K., Sawai, H., Hiroaki, H., Takenawa, T. & Itoh, T.
897 SH3YL1 regulates dorsal ruffle formation by a novel phosphoinositide-binding domain. *J Cell*
898 *Biol* **193**, 901-916, doi:10.1083/jcb.201012161 (2011).
- 899 66 Maekawa, M., Terasaka, S., Mochizuki, Y., Kawai, K., Ikeda, Y., Araki, N., Skolnik, E. Y.,
900 Taguchi, T. & Arai, H. Sequential breakdown of 3-phosphorylated phosphoinositides is
901 essential for the completion of macropinocytosis. *Proc Natl Acad Sci U S A* **111**, E978-987,
902 doi:10.1073/pnas.1311029111 (2014).
- 903 67 Balla, A. & Balla, T. Phosphatidylinositol 4-kinases: old enzymes with emerging functions.
904 *Trends Cell Biol* **16**, 351-361, doi:10.1016/j.tcb.2006.05.003 (2006).
- 905 68 Santos Mde, S., Naal, R. M., Baird, B. & Holowka, D. Inhibitors of PI(4,5)P2 synthesis reveal
906 dynamic regulation of IgE receptor signaling by phosphoinositides in RBL mast cells. *Mol*
907 *Pharmacol* **83**, 793-804, doi:10.1124/mol.112.082834 (2013).
- 908 69 Naguib, A. Following the trail of lipids: Signals initiated by PI3K function at multiple cellular
909 membranes. *Sci Signal* **9**, re4, doi:10.1126/scisignal.aad7885 (2016).

- 910 70 Zhang, S. X., Duan, L. H., He, S. J., Zhuang, G. F. & Yu, X. Phosphatidylinositol 3,4-
911 bisphosphate regulates neurite initiation and dendrite morphogenesis via actin aggregation.
912 *Cell Res* **27**, 253-273, doi:10.1038/cr.2017.13 (2017).
- 913 71 Gozzelino, L., De Santis, M. C., Gulluni, F., Hirsch, E. & Martini, M. PI(3,4)P2 Signaling in
914 Cancer and Metabolism. *Front Oncol* **10**, 360, doi:10.3389/fonc.2020.00360 (2020).
- 915 72 Kaplan, I. M., Wadia, J. S. & Dowdy, S. F. Cationic TAT peptide transduction domain enters
916 cells by macropinocytosis. *J Control Release* **102**, 247-253, doi:10.1016/j.jconrel.2004.10.018
917 (2005).
- 918 73 Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances
919 escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat Med* **10**, 310-315,
920 doi:10.1038/nm996 (2004).
- 921 74 Nakase, I., Niwa, M., Takeuchi, T., Sonomura, K., Kawabata, N., Koike, Y., Takehashi, M.,
922 Tanaka, S., Ueda, K., Simpson, J. C., Jones, A. T., Sugiura, Y. & Futaki, S. Cellular uptake of
923 arginine-rich peptides: roles for macropinocytosis and actin rearrangement. *Mol Ther* **10**,
924 1011-1022, doi:10.1016/j.ymthe.2004.08.010 (2004).
- 925 75 Polyakov, V., Sharma, V., Dahlheimer, J. L., Pica, C. M., Luker, G. D. & Piwnica-Worms, D.
926 Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into
927 human cells for imaging and radiotherapy. *Bioconjug Chem* **11**, 762-771,
928 doi:10.1021/bc000008y (2000).
- 929 76 Kawaguchi, Y., Takeuchi, T., Kuwata, K., Chiba, J., Hatanaka, Y., Nakase, I. & Futaki, S.
930 Syndecan-4 Is a Receptor for Clathrin-Mediated Endocytosis of Arginine-Rich Cell-Penetrating
931 Peptides. *Bioconjug Chem* **27**, 1119-1130, doi:10.1021/acs.bioconjchem.6b00082 (2016).
- 932 77 Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R. & Brock, R. A comprehensive model
933 for the cellular uptake of cationic cell-penetrating peptides. *Traffic* **8**, 848-866,
934 doi:10.1111/j.1600-0854.2007.00572.x (2007).
- 935 78 Yamauchi, Y. & Helenius, A. Virus entry at a glance. *J Cell Sci* **126**, 1289-1295,
936 doi:10.1242/jcs.119685 (2013).
- 937 79 Barbieri, M. A., Roberts, R. L., Gumusboga, A., Highfield, H., Alvarez-Dominguez, C., Wells, A.
938 & Stahl, P. D. Epidermal growth factor and membrane trafficking. EGF receptor activation of
939 endocytosis requires Rab5a. *J Cell Biol* **151**, 539-550 (2000).
- 940 80 Bucci, C., Lutcke, A., Steele-Mortimer, O., Olkkonen, V. M., Dupree, P., Chiariello, M., Bruni,
941 C. B., Simons, K. & Zerial, M. Co-operative regulation of endocytosis by three Rab5 isoforms.
942 *FEBS Lett* **366**, 65-71 (1995).
- 943 81 Roberts, R. L., Barbieri, M. A., Ullrich, J. & Stahl, P. D. Dynamics of rab5 activation in
944 endocytosis and phagocytosis. *J Leukoc Biol* **68**, 627-632 (2000).
- 945 82 Schnatwinkel, C., Christoforidis, S., Lindsay, M. R., Uttenweiler-Joseph, S., Wilm, M., Parton,
946 R. G. & Zerial, M. The Rab5 effector Rabankyrin-5 regulates and coordinates different
947 endocytic mechanisms. *PLoS biology* **2**, E261-E261, doi:10.1371/journal.pbio.0020261 (2004).
- 948 83 Kalia, M., Kumari, S., Chadda, R., Hill, M. M., Parton, R. G. & Mayor, S. Arf6-independent GPI-
949 anchored Protein-enriched Early Endosomal Compartments Fuse with Sorting Endosomes via
950 a Rab5/Phosphatidylinositol-3' -Kinase-dependent Machinery. *Molecular Biology of the Cell*
951 **17**, 3689-3704, doi:10.1091/mbc.e05-10-0980 (2006).
- 952 84 Duclos, S., Diez, R., Garin, J., Papadopoulou, B., Descoteaux, A., Stenmark, H. & Desjardins,
953 M. Rab5 regulates the kiss and run fusion between phagosomes and endosomes and the
954 acquisition of phagosome leishmanicidal properties in RAW 264.7 macrophages. *Journal of*
955 *Cell Science* **113**, 3531-3541 (2000).
- 956 85 Pelkmans, L., Burli, T., Zerial, M. & Helenius, A. Caveolin-stabilized membrane domains as
957 multifunctional transport and sorting devices in endocytic membrane traffic. *Cell* **118**, 767-
958 780, doi:10.1016/j.cell.2004.09.003 (2004).
- 959 86 Smith, J. L., Campos, S. K., Wandinger-Ness, A. & Ozbun, M. A. Caveolin-1-Dependent
960 Infectious Entry of Human Papillomavirus Type 31 in Human Keratinocytes Proceeds to the

- 961 Endosomal Pathway for pH-Dependent Uncoating. *Journal of Virology* **82**, 9505-9512,
962 doi:10.1128/jvi.01014-08 (2008).
- 963 87 Frittoli, E., Palamidessi, A., Pizzigoni, A., Lanzetti, L., Garrè, M., Troglio, F., Troilo, A., Fukuda,
964 M., Di Fiore, P. P., Scita, G. & Confalonieri, S. *The Primate-specific Protein TBC1D3 Is Required*
965 *for Optimal Macropinocytosis in a Novel ARF6-dependent Pathway*. Vol. 19 (2008).
- 966 88 Homma, Y., Kinoshita, R., Kuchitsu, Y., Wawro, P. S., Marubashi, S., Oguchi, M. E., Ishida, M.,
967 Fujita, N. & Fukuda, M. Comprehensive knockout analysis of the Rab family GTPases in
968 epithelial cells. *J Cell Biol* **218**, 2035-2050, doi:10.1083/jcb.201810134 (2019).
- 969 89 Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An auxin-based
970 degron system for the rapid depletion of proteins in nonplant cells. *Nat Methods* **6**, 917-922,
971 doi:10.1038/nmeth.1401 (2009).
- 972 90 Simpson, J. C., Griffiths, G., Wessling-Resnick, M., Fransen, J. A., Bennett, H. & Jones, A. T. A
973 role for the small GTPase Rab21 in the early endocytic pathway. *J Cell Sci* **117**, 6297-6311,
974 doi:10.1242/jcs.01560 (2004).
- 975 91 Pellinen, T., Arjonen, A., Vuoriluoto, K., Kallio, K., Fransen, J. A. & Ivaska, J. Small GTPase
976 Rab21 regulates cell adhesion and controls endosomal traffic of beta1-integrins. *J Cell Biol*
977 **173**, 767-780, doi:10.1083/jcb.200509019 (2006).
- 978 92 Zhang, X., He, X., Fu, X. Y. & Chang, Z. Varp is a Rab21 guanine nucleotide exchange factor
979 and regulates endosome dynamics. *J Cell Sci* **119**, 1053-1062, doi:10.1242/jcs.02810 (2006).
- 980 93 Junutula, J. R., De Maziere, A. M., Peden, A. A., Ervin, K. E., Advani, R. J., van Dijk, S. M.,
981 Klumperman, J. & Scheller, R. H. Rab14 is involved in membrane trafficking between the
982 Golgi complex and endosomes. *Mol Biol Cell* **15**, 2218-2229, doi:10.1091/mbc.e03-10-0777
983 (2004).
- 984 94 Ullrich, O., Reinsch, S., Urbe, S., Zerial, M. & Parton, R. G. Rab11 regulates recycling through
985 the pericentriolar recycling endosome. *J Cell Biol* **135**, 913-924 (1996).
- 986 95 Proikas-Cezanne, T., Gaugel, A., Frickey, T. & Nordheim, A. Rab14 is part of the early
987 endosomal clathrin-coated TGN microdomain. *FEBS Lett* **580**, 5241-5246,
988 doi:10.1016/j.febslet.2006.08.053 (2006).
- 989 96 Weimershaus, M., Mauvais, F. X., Saveanu, L., Adiko, C., Babdor, J., Abramova, A.,
990 Montealegre, S., Lawand, M., Evnouchidou, I., Huber, K. J., Chadt, A., Zwick, M., Vargas, P.,
991 Dussiot, M., Lennon-Dumenil, A. M., Brocker, T., Al-Hasani, H. & van Ender, P. Innate
992 Immune Signals Induce Anterograde Endosome Transport Promoting MHC Class I Cross-
993 Presentation. *Cell Rep* **24**, 3568-3581, doi:10.1016/j.celrep.2018.08.041 (2018).
- 994 97 Linford, A., Yoshimura, S., Nunes Bastos, R., Langemeyer, L., Gerondopoulos, A., Rigden, D. J.
995 & Barr, F. A. Rab14 and its exchange factor FAM116 link endocytic recycling and adherens
996 junction stability in migrating cells. *Dev Cell* **22**, 952-966, doi:10.1016/j.devcel.2012.04.010
997 (2012).
- 998 98 Kauppi, M., Simonsen, A., Bremnes, B., Vieira, A., Callaghan, J., Stenmark, H. & Olkkonen, V.
999 M. The small GTPase Rab22 interacts with EEA1 and controls endosomal membrane
1000 trafficking. *J Cell Sci* **115**, 899-911 (2002).
- 1001 99 Rodriguez-Gabin, A. G., Cammer, M., Almazan, G., Charron, M. & Larocca, J. N. Role of
1002 rRAB22b, an oligodendrocyte protein, in regulation of transport of vesicles from trans Golgi
1003 to endocytic compartments. *J Neurosci Res* **66**, 1149-1160, doi:10.1002/jnr.1253 (2001).
- 1004 100 Mishra, A., Eathiraj, S., Corvera, S. & Lambright, D. G. Structural basis for Rab GTPase
1005 recognition and endosome tethering by the C2H2 zinc finger of Early Endosomal Autoantigen
1006 1 (EEA1). *Proc Natl Acad Sci U S A* **107**, 10866-10871, doi:10.1073/pnas.1000843107 (2010).
- 1007 101 Di Nardo, A. A., Fuchs, J., Joshi, R. L., Moya, K. L. & Prochiantz, A. The Physiology of
1008 Homeoprotein Transduction. *Physiol Rev* **98**, 1943-1982, doi:10.1152/physrev.00018.2017
1009 (2018).
- 1010 102 Prochiantz, A. & Di Nardo, A. A. Homeoprotein signaling in the developing and adult nervous
1011 system. *Neuron* **85**, 911-925, doi:10.1016/j.neuron.2015.01.019 (2015).

- 1012 103 Spatazza, J., Di Lullo, E., Joliot, A., Dupont, E., Moya, K. L. & Prochiantz, A. Homeoprotein
1013 signaling in development, health, and disease: a shaking of dogmas offers challenges and
1014 promises from bench to bed. *Pharmacol Rev* **65**, 90-104, doi:10.1124/pr.112.006577 (2013).
- 1015 104 Sagan, S., Burlina, F., Alves, I. D., Bechara, C., Dupont, E. & Joliot, A. Homeoproteins and
1016 homeoprotein-derived peptides: going in and out. *Curr Pharm Des* **19**, 2851-2862,
1017 doi:10.2174/1381612811319160002 (2013).
- 1018 105 Rekaik, H., Blaudin de The, F. X., Fuchs, J., Massiani-Beaudoin, O., Prochiantz, A. & Joshi, R. L.
1019 Engrailed Homeoprotein Protects Mesencephalic Dopaminergic Neurons from Oxidative
1020 Stress. *Cell Rep* **13**, 242-250, doi:10.1016/j.celrep.2015.08.076 (2015).
- 1021 106 Rekaik, H., Blaudin de The, F. X., Prochiantz, A., Fuchs, J. & Joshi, R. L. Dissecting the role of
1022 Engrailed in adult dopaminergic neurons--Insights into Parkinson disease pathogenesis. *FEBS*
1023 *Lett* **589**, 3786-3794, doi:10.1016/j.febslet.2015.10.002 (2015).
- 1024 107 Blaudin de The, F. X., Rekaik, H., Peze-Heidsieck, E., Massiani-Beaudoin, O., Joshi, R. L., Fuchs,
1025 J. & Prochiantz, A. Engrailed homeoprotein blocks degeneration in adult dopaminergic
1026 neurons through LINE-1 repression. *EMBO J* **37**, doi:10.15252/embj.201797374 (2018).
- 1027 108 Alvarez-Fischer, D., Fuchs, J., Castagner, F., Stettler, O., Massiani-Beaudoin, O., Moya, K. L.,
1028 Bouillot, C., Oertel, W. H., Lombes, A., Faigle, W., Joshi, R. L., Hartmann, A. & Prochiantz, A.
1029 Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I
1030 insults. *Nat Neurosci* **14**, 1260-1266, doi:10.1038/nn.2916 (2011).
- 1031 109 Sugiyama, S., Di Nardo, A. A., Aizawa, S., Matsuo, I., Volovitch, M., Prochiantz, A. & Hensch, T.
1032 K. Experience-dependent transfer of Otx2 homeoprotein into the visual cortex activates
1033 postnatal plasticity. *Cell* **134**, 508-520, doi:10.1016/j.cell.2008.05.054 (2008).
- 1034 110 Torero Ibad, R., Rheey, J., Mrejen, S., Forster, V., Picaud, S., Prochiantz, A. & Moya, K. L. Otx2
1035 promotes the survival of damaged adult retinal ganglion cells and protects against excitotoxic
1036 loss of visual acuity in vivo. *J Neurosci* **31**, 5495-5503, doi:10.1523/JNEUROSCI.0187-11.2011
1037 (2011).
- 1038 111 Minois, N., Carmona-Gutierrez, D. & Madeo, F. Polyamines in aging and disease. *Aging*
1039 (*Albany NY*) **3**, 716-732, doi:10.18632/aging.100361 (2011).
- 1040 112 Miller-Fleming, L., Olin-Sandoval, V., Campbell, K. & Ralser, M. Remaining Mysteries of
1041 Molecular Biology: The Role of Polyamines in the Cell. *J Mol Biol* **427**, 3389-3406,
1042 doi:10.1016/j.jmb.2015.06.020 (2015).
- 1043 113 Arruabarrena-Aristorena, A., Zabala-Letona, A. & Carracedo, A. Oil for the cancer engine: The
1044 cross-talk between oncogenic signaling and polyamine metabolism. *Sci Adv* **4**, eaar2606,
1045 doi:10.1126/sciadv.aar2606 (2018).
- 1046 114 Handa, A. K., Fatima, T. & Mattoo, A. K. Polyamines: Bio-Molecules with Diverse Functions in
1047 Plant and Human Health and Disease. *Front Chem* **6**, 10, doi:10.3389/fchem.2018.00010
1048 (2018).
- 1049 115 Ramani, D., De Bandt, J. P. & Cynober, L. Aliphatic polyamines in physiology and diseases. *Clin*
1050 *Nutr* **33**, 14-22, doi:10.1016/j.clnu.2013.09.019 (2014).
- 1051 116 Soulet, D., Covassin, L., Kaouass, M., Charest-Gaudreault, R., Audette, M. & Poulin, R. Role of
1052 endocytosis in the internalization of spermidine-C(2)-BODIPY, a highly fluorescent probe of
1053 polyamine transport. *Biochem J* **367**, 347-357, doi:10.1042/BJ20020764 (2002).
- 1054 117 Soulet, D., Gagnon, B., Rivest, S., Audette, M. & Poulin, R. A fluorescent probe of polyamine
1055 transport accumulates into intracellular acidic vesicles via a two-step mechanism. *J Biol Chem*
1056 **279**, 49355-49366, doi:10.1074/jbc.M401287200 (2004).
- 1057 118 Uemura, T., Stringer, D. E., Blohm-Mangone, K. A. & Gerner, E. W. Polyamine transport is
1058 mediated by both endocytic and solute carrier transport mechanisms in the gastrointestinal
1059 tract. *Am J Physiol Gastrointest Liver Physiol* **299**, G517-522, doi:10.1152/ajpgi.00169.2010
1060 (2010).
- 1061 119 van Veen, S., Martin, S., Van den Haute, C., Benoy, V., Lyons, J., Vanhoutte, R., Kahler, J. P.,
1062 Decuypere, J. P., Gelders, G., Lambie, E., Zielich, J., Swinnen, J. V., Annaert, W., Agostinis, P.,

- 1063 Ghesquiere, B., Verhelst, S., Baekelandt, V., Eggermont, J. & Vangheluwe, P. ATP13A2
1064 deficiency disrupts lysosomal polyamine export. *Nature* **578**, 419-424, doi:10.1038/s41586-
1065 020-1968-7 (2020).
- 1066 120 Klopper, T. H., Kienle, N., Fasshauer, D. & Munro, S. Untangling the evolution of Rab G
1067 proteins: implications of a comprehensive genomic analysis. *BMC Biol* **10**, 71,
1068 doi:10.1186/1741-7007-10-71 (2012).
- 1069 121 Palm, W. Metabolic functions of macropinocytosis. *Philos Trans R Soc Lond B Biol Sci* **374**,
1070 20180285, doi:10.1098/rstb.2018.0285 (2019).
- 1071 122 Toshima, J. Y., Nishinoaki, S., Sato, Y., Yamamoto, W., Furukawa, D., Siekhaus, D. E.,
1072 Sawaguchi, A. & Toshima, J. Bifurcation of the endocytic pathway into Rab5-dependent and -
1073 independent transport to the vacuole. *Nat Commun* **5**, 3498, doi:10.1038/ncomms4498
1074 (2014).
- 1075 123 Shimamura, H., Nagano, M., Nakajima, K., Toshima, J. Y. & Toshima, J. Rab5-independent
1076 activation and function of yeast Rab7-like protein, Ypt7p, in the AP-3 pathway. *PLoS One* **14**,
1077 e0210223, doi:10.1371/journal.pone.0210223 (2019).
- 1078 124 Tebaldi, G., Pritchard, S. M. & Nicola, A. V. Herpes Simplex Virus Entry by a Nonconventional
1079 Endocytic Pathway. *J Virol* **94**, doi:10.1128/JVI.01910-20 (2020).
- 1080 125 Castano-Rodriguez, C., Honrubia, J. M., Gutierrez-Alvarez, J., DeDiego, M. L., Nieto-Torres, J.
1081 L., Jimenez-Guardeno, J. M., Regla-Nava, J. A., Fernandez-Delgado, R., Verdia-Baguena, C.,
1082 Queralt-Martin, M., Kochan, G., Perlman, S., Aguilera, V. M., Sola, I. & Enjuanes, L. Role of
1083 Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a in Replication and
1084 Pathogenesis. *MBio* **9**, doi:10.1128/mBio.02325-17 (2018).
- 1085 126 Quirin, K., Eschli, B., Scheu, I., Poort, L., Kartenbeck, J. & Helenius, A. Lymphocytic
1086 choriomeningitis virus uses a novel endocytic pathway for infectious entry via late
1087 endosomes. *Virology* **378**, 21-33, doi:S0042-6822(08)00294-8 [pii]
1088 10.1016/j.virol.2008.04.046 (2008).
- 1089 127 Rojek, J. M., Perez, M. & Kunz, S. Cellular entry of lymphocytic choriomeningitis virus. *J Virol*
1090 **82**, 1505-1517, doi:10.1128/JVI.01331-07 (2008).
- 1091 128 Kunz, S. Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of
1092 virus-host interaction. *Virology* **387**, 245-249, doi:10.1016/j.virol.2009.02.042 (2009).
- 1093 129 Pasqual, G., Rojek, J. M., Masin, M., Chatton, J. Y. & Kunz, S. Old world arenaviruses enter the
1094 host cell via the multivesicular body and depend on the endosomal sorting complex required
1095 for transport. *PLoS Pathog* **7**, e1002232, doi:10.1371/journal.ppat.1002232 (2011).
- 1096 130 Kunz, S. & de la Torre, J. C. Breaking the Barrier: Host Cell Invasion by Lujo Virus. *Cell Host*
1097 *Microbe* **22**, 583-585, doi:10.1016/j.chom.2017.10.014 (2017).
- 1098 131 Raaben, M., Jae, L. T., Herbert, A. S., Kuehne, A. I., Stubbs, S. H., Chou, Y. Y., Blomen, V. A.,
1099 Kirchhausen, T., Dye, J. M., Brummelkamp, T. R. & Whelan, S. P. NRP2 and CD63 Are Host
1100 Factors for Lujo Virus Cell Entry. *Cell Host Microbe* **22**, 688-696 e685,
1101 doi:10.1016/j.chom.2017.10.002 (2017).
- 1102 132 Wu, Q. M., Liu, S. L., Chen, G., Zhang, W., Sun, E. Z., Xiao, G. F., Zhang, Z. L. & Pang, D. W.
1103 Uncovering the Rab5-Independent Autophagic Trafficking of Influenza A Virus by Quantum-
1104 Dot-Based Single-Virus Tracking. *Small* **14**, e1702841, doi:10.1002/smll.201702841 (2018).
- 1105 133 Fan, J., Liu, X., Mao, F., Yue, X., Lee, I. & Xu, Y. Proximity proteomics identifies novel function
1106 of Rab14 in trafficking of Ebola virus matrix protein VP40. *Biochem Biophys Res Commun* **527**,
1107 387-392, doi:10.1016/j.bbrc.2020.04.041 (2020).
- 1108 134 Okai, B., Lyall, N., Gow, N. A., Bain, J. M. & Erwig, L. P. Rab14 regulates maturation of
1109 macrophage phagosomes containing the fungal pathogen *Candida albicans* and outcome of
1110 the host-pathogen interaction. *Infect Immun* **83**, 1523-1535, doi:10.1128/IAI.02917-14
1111 (2015).
- 1112 135 Mrozowska, P. S. & Fukuda, M. Regulation of podocalyxin trafficking by Rab small GTPases in
1113 2D and 3D epithelial cell cultures. *J Cell Biol* **213**, 355-369, doi:10.1083/jcb.201512024 (2016).

1114 136 Jordan, M., Schallhorn, A. & Wurm, F. M. Transfecting mammalian cells: optimization of
1115 critical parameters affecting calcium-phosphate precipitate formation. *Nucleic Acids Res* **24**,
1116 596-601 (1996).

1117




Figure 1




Figure 2




Figure 3




Figure 4




Figure S1




Figure S2




Figure S3




Figure S4




Figure S5




Figure S6